The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.
  • The agreement for the distribution of Sentia runs for three years and can be renewed and terminated by either company
  • Sentia analyses sulphur dioxide in post-fermentation white and red wine in a quick and accurate manner
  • Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage
  • UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents

Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.

The distribution period for the Sentia device runs for three years and can be renewed and terminated by either company.

“We are delighted to partner with Sentia in the United States. We have received positive feedback from our customers and believe Sentia will make a significant impact in the wine testing market in the USA,” Wine & Beer Supply CEO Dave Robertson said.

It’s been a busy couple of days for UBI, entering an agreement with Singularity SpA for the distribution of Sentia in Chile just yesterday.

Sentia analyses sulphur dioxide in post-fermentation white and red wine. Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage.

Results are then received in under a minute instead of the several days it takes a lab.

“Securing another distributor in the U.S. is a positive step in the commercialisation of Sentia globally,” UBI CEO John Sharman commented.

“Wine & Beer Supply has a strong presence in the U.S., particularly in the eastern half of the U.S. and will give Sentia greater access to the 11,500 wineries across the country,” he added.

UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents in a $129.6 million market cap.

UBI by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…